Bacillus subtilis contains 10 rRNA (rrn) operons. We found that rRNA operon-engineered B. subtilis strain RIK543, with only the rrnO operon, is specifically hypersensitive to RNA polymerase inhibitors such as rifamycin SV and rifampin (80-fold and 20-fold, respectively). In pilot screening experiments, we found actinomycete isolates successfully at an incidence of 1.9% (18/945) that produced antibacterials that were detectable only with RIK543 as the test organism. Strain RIK543 may be a feasible test organism for the discovery of novel RNA polymerase inhibitors.
T
he rate of discovery of medically useful compounds has declined since 1970, although there is a constant need for new and improved drugs to combat infectious diseases, cancer, and other major life-threatening conditions. With recent advances in DNA sequencing technologies, it is now feasible to sequence multiple actinomycete genomes both rapidly and inexpensively. Given that there are many cryptic secondary metabolite gene clusters in actinomycetes (1) (2) (3) (4) , there is a great deal of interest in the activation/exploitation of biosynthetic pathways for useful metabolites (5, 6) . Such cryptic biosynthetic pathways have the potential to deliver a multitude of novel bioactive compounds that may rejuvenate stalling drug discovery pipelines. In addition to enhancement of productivity, it is also important to construct a sensitive detection system to discover novel secondary metabolites. In particular, a sensitive bioassay system may be effective in identifying novel antibiotics. A more important but difficult aspect of antibiotic discovery is the determination of which antibacterial compounds are worth the effort of further characterization and purification (in the case of natural products) or chemical modification (for synthetic compounds). In the course of studying rRNA (rrn) operon-engineered Bacillus subtilis strains, we found that a B. subtilis strain with a single rrn operon is highly sensitive specifically to antibiotics that inhibit RNA polymerase (RNAP) reactions. Bacterial RNAP is a proven target for broadspectrum antibacterial therapy and for antituberculosis therapy (7-10). Although a major risk of targeting RNAP is the highfrequency appearance of resistant mutants that is observed for rifampin, RNAP is a suitable target for the following reasons: (i) RNAP is an essential enzyme for the viability of any microorganisms (permits efficacy), (ii) bacterial RNAP subunit sequences are highly conserved (permits broad-spectrum activity), (iii) bacterial RNAP sequences and eukaryotic RNAP sequences are less highly conserved (permits therapeutic selectivity), (iv) RNAP performs several enzymatic reactions and interacts with a large number of regulators (permits numerous potential targets for interference by antibiotics), and (v) rifamycins have retained their position as first-line antibiotics for tuberculosis therapy worldwide even at the present time (permits reliability) (11, 12) . The present study provides a new strategy for the efficient discovery of novel RNAP inhibitors on the basis of our finding that an rRNA operon-engineered B. subtilis strain with only the rrnO operon exhibits hypersusceptibility specifically to RNAP inhibitors such as rifamycins.
Most rRNA (rrn) operons in bacterial cells are composed of three rRNA genes, which encode 16S, 23S, and 5S rRNAs, in that order. The genomes of Escherichia coli and B. subtilis contain 7 and 10 rrn operons, respectively (13, 14) . In general, organisms that possess multiple rrn operons are considered to be able to grow faster than those that possess one or two operons. However, it is possible to delete one rRNA operon in either E. coli or B. subtilis without significantly affecting its cell growth rate or physiology (15, 16) , which suggests that the full number of copies of the rRNA operon is not required for the rapid growth of these two organisms, at least under laboratory conditions. In B. subtilis, 10 rrn operons (rrnO, rrnA, rrnJ, rrnW, rrnI, rrnH, rrnG, rrnE, rrnD, and rrnB), which include the rrnJ-rrnW and rrnI-rrnH-rrnG clusters, have been identified (16) (17) (18) . Recently, Nanamiya et al. (19) sequentially deleted the rrn operons from B. subtilis strain 168(trpC2) and constructed seven mutant strains, each of which harbored a single rrn operon (rrnA, rrnB, rrnD, rrnE, rrnI, rrnJ, or rrnO) in its genome. One of these strains, RIK543 (trpC2 ⌬rrnHG1 ⌬rrnD1 ⌬rrnE1 ⌬rrnB2 ⌬rrnA1 ⌬rrnI2 ⌬rrnW2 ⌬rrnJ1::cat [⌬9 rrnO ϩ ]), with only one rrnO operon, was used in this study. Briefly, the method used to construct RIK543 was based on the "ampicillin screening" technique, as described in detail previously (19) . The existence of only one rrnO operon in the genome of RIK543 was confirmed by Southern blotting. Strain RIK543, similar to other engineered strains harboring only a single rrn operon, shows a reduced growth rate (doubling time, 23 min for parent strain 168 but 69 min for RIK543), probably because of a decreased level of ribosomes in the mutant (19) . Spontaneous suppressor mutants that are able to grow faster than RIK543 often appear after sequential inoculation onto LB plates. One of these suppressor mutants, RIK606 (doubling time, 31 min), with five rrnO copies (as determined by both Southern hybridization and real-time quan-titative PCR), was also used in this study. Thus, strains 168, RIK543, and RIK606 are isogenic to each other. LB medium, consisting of 1% tryptone (Difco), 0.5% yeast extract (Difco), and 0.5% NaCl (adjusted to pH 7.2 with NaOH), was used throughout this study to grow B. subtilis strains. Sequencing of the actinomycete 16S rRNA (about 1,400 bp) was conducted as described previously by Talà et al. (20) .
First, we compared the susceptibilities of the wild-type (168) and mutant (RIK543 and RIK606) strains to various antibiotics that are known to inhibit DNA synthesis, RNA synthesis, protein synthesis, cell wall synthesis, etc. (Table 1) . Antibiotics were mixed with LB agar before plates were poured. Ten-microliter cell suspensions (ϳ10 6 ) were then spotted onto the plates containing various concentrations of each antibiotic. The MIC was defined as the lowest concentration of the antibiotic to fully inhibit growth during a 20-h incubation at 37°C. Strikingly, RIK543 showed hypersusceptibility to RNAP inhibitors, such as rifamycin SV and rifampin (a semisynthetic antibiotic derived from rifamycin SV), with 80-fold and 20-fold greater susceptibilities than the wild type, respectively. B. subtilis was not highly susceptible to fidaxomicin (MIC ϭ 5 g/ml), and the susceptibility of RIK543 to this antibiotic was only 5-fold greater (MIC ϭ 1 g/ml). Similar results were obtained when Mueller-Hinton medium (a standard medium for MIC determination) was used instead of LB medium (Table 1) . ␣-Amanitin, which is known to inhibit eukaryotic RNAP specifically, did not inhibit the growth of either the wild type or RIK543. Susceptibility to other antibiotics was altered only marginally. Thus, RIK543 is specifically hypersensitive to inhibitors of RNAP. The observed hypersensitivity of RIK543 to RNAP inhibitors was apparently due to the reduced number of rrn operons, as strain RIK606, with five rrnO copies, showed intermediate susceptibility ( Table 1) .
The results presented above raise the possibility that RIK543 is a feasible test organism for use in searching for novel antibiotics, especially RNAP inhibitors. We conducted screening experiments to assess this possibility. First, 945 actinomycete strains isolated from soil were grown on GYM agar plates at 30°C for 5 days, and then agar plugs 12 mm in diameter cut from the plates were laid on LB agar medium inoculated with B. subtilis strain 168 and incubated at 37°C for 24 h to detect growth inhibition zones. A total of 307 isolates (32% of those examined) were found not to produce growth inhibition zones on bioassay plates. These 307 isolates were then subjected to a bioassay with RIK543 as the test organism. Thirty-three isolates (11% of those examined) were found to produce compounds with detectable antibacterial activity against RIK543. Importantly, of the antibacterials detected in the 33 isolates, those detected in 18 isolates were not detectable even if Staphylococcus aureus 209P was used as the test organism. Thus, we found actinomycete isolates successfully at an incidence of 1.9% (18/945) that produced antibacterials that were detectable only with RIK543 as the test organism. The identification of isolates with this phenotype in the pilot screening supports the potential value of strains RIK543 and 168 for screening or for the evaluation of hits. Bioassay profiles of three representative actinomycete isolates (strains 2, 5, and 51) are shown in Fig. 1 and Streptomyces fulvoviolaceus, as determined by 16S rRNA sequence analysis. It is possible to evaluate the antibacterials produced by these 18 isolates, for example, by testing activity against RIK543 and a rifamycin-resistant mutant strain derived from RIK543 to assess for rifamycin-like or non-rifamycin-like activity.
Once an antibacterial(s) is found not to be like rifamycin, it might be extracted with organic solvent for further characterization and purification.
Rifamycins are macrocyclic antibacterial agents of the ansamycin family, bind to a site on bacterial RNAP adjacent to the RNAP active center, and prevent the extension of RNA chains beyond a length of 2 or 3 nucleotides (21, 22) . The rifamycins are in current clinical use for the treatment of both Grampositive and Gram-negative bacterial infections. However, the clinical utility of rifamycins is threatened by the occurrence of resistant bacterial strains. Antibiotics with different binding sites on the enzyme and different mechanism of inhibition are therefore urgently required. To date, four antibiotics (myxopyronin, corallopyronin, ripostatin, and lipiarmycin) that function through the new RNAP target have been identified (11) . Of these, fidaxomicin (synonym of lipiarmycin A3) was recently approved by the U.S. Food and Drug Administration as a narrow-spectrum antibacterial agent for the treatment of Clostridium difficile infections (12, 23) . The value of strain RIK543 is its ability to distinguish inhibitors of the pathway of interest from the large number of antibacterial compounds that may not be of interest. Thus, the remarkably differential susceptibilities of RIK543 and its parent 168 provide a valuable secondary assay for the evaluation of hits from a primary screening-assuming that RNAP is a desirable antibiotic target. Given the urgent need for novel RNAP inhibitors, the use of RIK543 as a test organism may facilitate the discovery of new antibiotics that potently inhibit RNAP function, in combination with methods of early-stage yield enhancement (5, 6, 24, 25) to obtain enough material for chemical and biological characterization. 
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